General Biologicals Corporation (TPEX:4117)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.20
-0.25 (-2.39%)
Jul 30, 2026, 1:41 PM CST

General Biologicals Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
465.84-220.82-198.83-53.1944.14
Depreciation & Amortization
78.7737.636.0435.1834.97
Other Amortization
0.310.430.640.740.76
Loss (Gain) From Sale of Assets
-748.16--0.38-9.85
Loss (Gain) From Sale of Investments
2.91-3.05-4.89-0.445.82
Loss (Gain) on Equity Investments
-0.010.256.931.340.16
Stock-Based Compensation
12.5710.8---
Provision & Write-off of Bad Debts
0.752.64-3.88-3.71-15.74
Other Operating Activities
-16.433.6216.0116.51-5.54
Change in Accounts Receivable
11.13-65.0225.81-14.9133.32
Change in Inventory
-1.8830.9331.24-35.47-18.48
Change in Accounts Payable
3.3259.52-0.79-10.01-1.63
Change in Unearned Revenue
17.6524.430.661.51-3.78
Change in Other Net Operating Assets
45.98-71.02316.75287.08-10.18
Operating Cash Flow
-127.26-189.68225.68225.0138.97
Operating Cash Flow Growth
--0.30%477.34%-16.62%

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-180.02-1,545-424.02-248.42-14.73
Sale of Property, Plant & Equipment
---2.191.51
Cash Acquisitions
--0.92---
Divestitures
-5.61----
Sale (Purchase) of Intangibles
-0.45-0.85-1-0.18-2.59
Investment in Securities
--88.9-29.6559.04
Other Investing Activities
2.15-8.24-6.19-1.84-118.98
Investing Cash Flow
-183.92-1,555-342.31-277.91-75.76

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
150150505-
Long-Term Debt Issued
345.891,71835-5
Total Debt Issued
495.891,8688555
Short-Term Debt Repaid
-150-140-5--
Long-Term Debt Repaid
-177.79-21.99-7.63-14.74-9.26
Total Debt Repaid
-327.79-161.99-12.63-14.74-9.26
Net Debt Issued (Repaid)
168.111,70672.37-9.74-4.26
Issuance of Common Stock
120----
Other Financing Activities
19.34----
Financing Cash Flow
307.451,70672.37-9.74-4.26

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-4.5673.5-0.8116.05-0.79
Net Cash Flow
-8.334.52-45.06-46.59-41.83

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-307.28-1,735-198.33-23.4224.24
Free Cash Flow Growth
----3.23%
Free Cash Flow Margin
-142.43%-688.57%-74.89%-6.32%4.40%
Free Cash Flow Per Share
-4.91-29.00-3.31-0.390.41
Levered Free Cash Flow
-108.3-2,334291.73-291.8327.32
Unlevered Free Cash Flow
-82.18-2,325299.22-281.2934.19

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
30.888.467.147.3211
Change in Working Capital
76.2-21.15373.67228.19-15.76